TY - JOUR
T1 - Management of locoregional recurrence after radical resection of a primary nonmetastatic retroperitoneal soft tissue sarcoma
T2 - The Gustave Roussy experience
AU - Honoré, Charles
AU - Faron, Matthieu
AU - Mir, Olivier
AU - Haddag-Miliani, Leila
AU - Dumont, Sarah
AU - Terrier, Philippe
AU - LePéchoux, Cecile
AU - Botticella, Angela
AU - Adam, Julien
AU - Le Cesne, Axel
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2018/12/15
Y1 - 2018/12/15
N2 - Background: Despite surgery, many patients experience locoregional recurrence (LR), the optimum treatment of which is still debated. Methods: All 297 consecutive patients operated for a nonmetastatic primary retroperitoneal soft tissue sarcoma (RPS) between 1994 and 2017 were retrospectively analyzed to report our experience in treating LR. Results: After a median follow-up of 97 months, 55 patients (19%) developed LR. The first site of recurrence was locoregional in 100% with associated peritoneal metastases in 45% and distant metastases in 5%. After LR treatment, the 1-, 3-, and 5-year overall survival (OS) rates were 71%, 46%, and 33%. Low tumor grade, disease-free interval above 24 months, exclusive LR, and well-differentiated liposarcoma were predictive of better OS. The treatment strategy (best supportive care, chemotherapy radiotherapy, and/or surgery) was not statistically significant. Fourteen patients underwent initial surveillance (strategic delay) for low-grade LR and eventually required treatment in 86% after a median delay of 20 months during which no patient developed distant metastases. Conclusions: The management of LR in RPS is complex. An initial surveillance may not alter survival in asymptomatic low-grade and slow-growing LR. An LR decision scheme is proposed.
AB - Background: Despite surgery, many patients experience locoregional recurrence (LR), the optimum treatment of which is still debated. Methods: All 297 consecutive patients operated for a nonmetastatic primary retroperitoneal soft tissue sarcoma (RPS) between 1994 and 2017 were retrospectively analyzed to report our experience in treating LR. Results: After a median follow-up of 97 months, 55 patients (19%) developed LR. The first site of recurrence was locoregional in 100% with associated peritoneal metastases in 45% and distant metastases in 5%. After LR treatment, the 1-, 3-, and 5-year overall survival (OS) rates were 71%, 46%, and 33%. Low tumor grade, disease-free interval above 24 months, exclusive LR, and well-differentiated liposarcoma were predictive of better OS. The treatment strategy (best supportive care, chemotherapy radiotherapy, and/or surgery) was not statistically significant. Fourteen patients underwent initial surveillance (strategic delay) for low-grade LR and eventually required treatment in 86% after a median delay of 20 months during which no patient developed distant metastases. Conclusions: The management of LR in RPS is complex. An initial surveillance may not alter survival in asymptomatic low-grade and slow-growing LR. An LR decision scheme is proposed.
KW - recurrence
KW - sarcoma
KW - strategic delay
KW - surgery
KW - surveillance
UR - http://www.scopus.com/inward/record.url?scp=85056110470&partnerID=8YFLogxK
U2 - 10.1002/jso.25291
DO - 10.1002/jso.25291
M3 - Article
C2 - 30399202
AN - SCOPUS:85056110470
SN - 0022-4790
VL - 118
SP - 1318
EP - 1325
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 8
ER -